ASCO: Adjuvant denosumab halves fracture risk for breast cancer patients on AIs

CHICAGO – Adjuvant denosumab is efficacious and safe for reducing fracture risk among women taking aromatase inhibitors (AIs) as part of their treatment for early breast cancer, finds the Austrian...